Stada Steps In To Secure German Tamoxifen Supply
Aliud’s Import Of Italian Product From EG Will Bridge Supply Bottleneck In Germany
Stada says it is taking action to address current disruptions to the supply of tamoxifen in Germany, with the firm’s Aliud Pharma subsidiary bringing in supplies from Stada’s EG business in Italy.
You may also be interested in...
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.